/AELIS.PA
AELIS.PA Stock - Aelis Farma S.A.
Healthcare|BiotechnologyPAR
$1.07-2.73%
$0.03 (-2.73%) • Dec 23
63
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.33
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1.18
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for AELIS.PA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.06 – $1.08
TARGET (TP)$1.23
STOP LOSS$0.98
RISK/REWARD1:1.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.46
52W High$5.10
52W Low$0.67
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $2.68M | $9.05M | $3.81M | $9.07M | $1.14M |
| Gross Profit | $2.68M | $9.05M | $3.81M | $9.07M | $1.11M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 97.4% |
| Operating Income | $-7,735,000 | $-6,461,000 | $-8,525,000 | $2.55M | $-4,046,000 |
| Net Income | $-7,456,000 | $-5,078,000 | $-14,288,000 | $574,000 | $-2,086,000 |
| Net Margin | -278.4% | -56.1% | -375.1% | 6.3% | -183.5% |
| EPS | $-0.54 | $-0.39 | $-1.21 | $0.06 | $-0.22 |
Company Overview
Aelis Farma SA, a biotechnology company, engages in the research and development of treatments for brain diseases. It is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; and AEF0217, a drug candidate, which completed Phase 1 clinical trials to treat cognitive deficits observed in Down syndrome, as well as other cognitive impairments. The company was incorporated in 2013 and is based in Bordeaux, France.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
AELIS.PABeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.32
Q3 2025
EPS Surprise History
Q1 22
No data
Q4 22
No data
Q2 23
No data
Q3 23
No data
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q3 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2025 | Sep 22, 2025 | — | $-0.32 | — | — |
Q4 2024 | Dec 31, 2024 | — | $-0.28 | — | — |
Q3 2024 | Sep 25, 2024 | — | $-0.27 | — | — |
Q2 2024 | Apr 26, 2024 | — | $-0.26 | — | — |
Q3 2023 | Sep 25, 2023 | — | $-0.13 | — | — |
Q2 2023 | Apr 3, 2023 | — | $-0.31 | — | — |
Q4 2022 | Dec 16, 2022 | — | $-0.93 | — | — |
Q1 2022 | Feb 4, 2022 | — | $-0.33 | — | — |
Q2 2021 | Jun 30, 2021 | — | $0.31 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-0.07 | — | — |
Q2 2020 | Jun 30, 2020 | — | $-0.15 | — | — |
Q4 2019 | Dec 31, 2019 | — | $-0.17 | — | — |
Q2 2019 | Jun 30, 2019 | — | $-0.17 | — | — |
Q4 2018 | Dec 31, 2018 | — | $-0.14 | — | — |
Q2 2018 | Jun 30, 2018 | — | $-0.14 | — | — |
Q4 2017 | Dec 31, 2017 | — | $-0.05 | — | — |
Q2 2017 | Jun 30, 2017 | — | $-0.05 | — | — |
Latest News
Loading news...
Frequently Asked Questions about AELIS.PA
What is AELIS.PA's current stock price?
Aelis Farma S.A. (AELIS.PA) is currently trading at $1.07 per share. The stock has moved -2.73% today.
What is the analyst price target for AELIS.PA?
No analyst price targets are currently available for this stock.
What sector is Aelis Farma S.A. in?
Aelis Farma S.A. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the PAR exchange.
What is AELIS.PA's market cap?
Aelis Farma S.A. has a market capitalization of $0.01 billion, making it a small-cap company.
Does AELIS.PA pay dividends?
No, Aelis Farma S.A. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALDVI.PA
Advicenne S.A.
$1.75
Mkt Cap: $0.0B
ALINS.PA
Intrasense S.A.
$0.25
Mkt Cap: $0.0B
ALNFL.PA
NFL Biosciences S.A.
$1.16
Mkt Cap: $0.0B
ALPAT.PA
Plant Advanced Technologies S.A.
$8.46
Mkt Cap: $0.0B
ALPRE.PA
Predilife S.A.
$3.39
Mkt Cap: $0.0B
ALTHX.PA
THX Pharma
$2.02
Mkt Cap: $0.0B
ALTME.PA
TME Pharma N.V.
$0.06
Mkt Cap: $0.0B
ALVAL.PA
Valbiotis S.A.
$0.69
Mkt Cap: $0.0B
POXEL.PA
Poxel S.A.
$0.24
Mkt Cap: $0.0B
SIGHT.PA
GenSight Biologics S.A.
$0.11
Mkt Cap: $0.0B
Explore stocks similar to AELIS.PA for comparison